Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Fuji
Farmers Insurance
Julphar
Dow
Daiichi Sankyo
US Department of Justice
McKinsey
Federal Trade Commission

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,820,671

« Back to Dashboard

Which drugs does patent 7,820,671 protect, and when does it expire?

Patent 7,820,671 protects INCIVEK and is included in one NDA.

This patent has one hundred patent family members in thirty-five countries.
Summary for Patent: 7,820,671
Title:Peptidomimetic protease inhibitors
Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.
Inventor(s): Babine; Robert Edward (Carlsbad, CA), Chen; Shu Hui (Thousand Oaks, CA), Collado; Ivan (Madrid, ES), Garcia-Paredes; Cristina (Madrid, ES), Glass; John Irvin (Germantown, MD), Guo; Deqi (Carmel, IN), Jin; Ling (Indianapolis, IN), Lamar; Jason Eric (Indianapolis, IN), Parker, III; Raymond Samuel (Doylestown, PA), Snyder; Nancy June (Lizton, IN), Sun; Xicheng David (Broumfied, CO), Tebbe; Mark Joseph (Zionsville, IN), Victor; Frantz (Indianapolis, IN), Wang; Q. May (Indianapolis, IN), Yip; Yvonne Yee Mai (Indianapolis, IN), Perni; Robert B. (Marlborough, MA), Farmer; Luc (Foxborough, MA)
Assignee: Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Application Number:10/344,112
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,820,671

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Vertex Pharms INCIVEK telaprevir TABLET;ORAL 201917-001 May 23, 2011 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,820,671

PCT Information
PCT FiledAugust 31, 2001PCT Application Number:PCT/US01/26008
PCT Publication Date:March 07, 2002PCT Publication Number: WO02/18369

Non-Orange Book US Patents Family Members for Patent 7,820,671

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,252,923 Peptidomimetic protease inhibitors ➤ Try a Free Trial
8,529,882 Peptidomimetic protease inhibitors ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,820,671

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 030591 ➤ Try a Free Trial
Austria 431358 ➤ Try a Free Trial
Austria 483686 ➤ Try a Free Trial
Australia 2001288318 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Chubb
Medtronic
AstraZeneca
Merck
US Department of Justice
Express Scripts
Moodys
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.